Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature
Department of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(s1), 19-28; https://doi.org/10.3747/co.22.2363
Submission received: 12 December 2014
/
Revised: 13 January 2015
/
Accepted: 13 February 2015
/
Published: 1 March 2015
Abstract
Breast tumours positive for HER2 (human epidermal growth factor receptor 2) represent approximately 20% of all breast cancer cases and are associated with an aggressive natural history. The advent of targeted anti-HER2 therapies has dramatically improved disease control and survival in patients with metastatic HER2-positive breast cancer. Targeted agents are now considered the standard of care in the first-line setting and beyond. The present review summarizes the currently available data on targeted anti-HER2 therapies from completed randomized phase III clinical trials and briefly discusses emerging advances that will address unmet needs in metastatic HER2-positive breast cancer.
Keywords:
her2; metastatic breast cancer; targeted therapy; phase iii trials
Share and Cite
MDPI and ACS Style
Zhu, X.; Verma, S. Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature. Curr. Oncol. 2015, 22, 19-28. https://doi.org/10.3747/co.22.2363
AMA Style
Zhu X, Verma S. Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature. Current Oncology. 2015; 22(s1):19-28. https://doi.org/10.3747/co.22.2363
Chicago/Turabian StyleZhu, X., and S. Verma. 2015. "Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature" Current Oncology 22, no. s1: 19-28. https://doi.org/10.3747/co.22.2363
